Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D SenGupta
Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide From Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, FTC and TDF: 96-Week Results From Two Randomized Clinical Trials
HIV Medicine
Health Policy
Infectious Diseases
Pharmacology
Related publications
Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (FTC/TAF) vs. Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by Third Agent of a Randomized, Double-Blind, Active-Controlled Phase 3 Trial
HIV Clinical Trials
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide
Journal of the International Association of Providers of AIDS Care
Dermatology
Infectious Diseases
Immunology
First-Line Antiretroviral Therapy With Efavirenz Plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison
HIV Medicine
Health Policy
Infectious Diseases
Pharmacology
O015 Establishment of a Monitoring Service for Men Who Have Sex With Men (MSM) Taking Generic Co-Formulated Tenofovir Disoproxil Fumarate (TDF)/emtricitabine (FTC) as Pre-Exposure Prophylaxis (PrEP) Against HIV Infection
Sexually Transmitted Infections
Dermatology
Infectious Diseases
Switch From Tenofovir Disoproxil Fumarate Combination to Dolutegravir Plus Rilpivirine Improves Parameters of Bone Health
AIDS
Infectious Diseases
Allergy
Immunology
In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir With Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Emtricitabine, Tenofovir, and Rilpivirine From Their Degradation Products Analysis by HPLC
International Journal of Research in Pharmaceutical Sciences
Toxicology
Pharmaceutics
Pharmacology
96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study
Antiviral Therapy
Infectious Diseases
Pharmacology
Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid With FTC/TDF in Treatment-Naive HIV-1 Patients
Journal of AIDS & Clinical Research
